If you take oral semaglutide, take it on an empty stomach right after waking, with no more than about 4 oz (120 mL) of plain water, then wait at least 30 minutes before eating, drinking or taking other medications — food can lower the drug's absorption by about 40%. Injectable GLP-1 medications (Ozempic, Wegovy, Mounjaro/tirzepatide) have no food-timing requirement — they can be taken with or without food. In every case, the weight-loss result still depends on a sustained calorie deficit and regular physical activity.
A 2024 systematic review of semaglutide pharmacokinetics in Drug Design, Development and Therapy found that taking oral semaglutide with food significantly reduces drug exposure — the fed state lowered absorption by about 40% compared with fasting. The review's practical conclusion: take oral semaglutide on an empty stomach with water, and keep a 30-minute post-dose fasting window. The FDA-approved label says the same: take it upon waking with no more than 4 oz of plain water, and wait at least 30 minutes before eating, drinking or taking other oral medicines.
Take on an empty stomach when you wake up, with no more than 4 oz (about 120 mL) of plain water. Wait at least 30 minutes before food, drink or any other oral medication. Even coffee, tea or juice in that window counts.
No food-timing requirement — the FDA label and pharmacokinetic data show these can be taken with or without food. Choose a consistent day and time.
In the SURMOUNT-4 trial (JAMA, 2024), adults on tirzepatide followed a 500 kcal/day deficit diet and at least 150 minutes of weekly physical activity. Those who continued the drug lost an additional 5.5% of body weight over 52 weeks; those switched to placebo regained about 14%.
A 2024 NEJM trial of semaglutide in people with obesity and knee osteoarthritis showed that weight reduction alleviated knee pain and improved function — a reminder that the dietary pattern behind the weight loss matters as much as the drug.
Two 2025 NEJM trials studied orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity and for early type 2 diabetes. The obesity trial (72 weeks) found the highest dose (36 mg daily) produced a mean weight loss of about 11.2%; the type 2 diabetes trial (40 weeks, doses 3/12/36 mg daily, starting at 1 mg with 4-week escalations) reduced both HbA1c and body weight.
The 2025 NEJM type 2 diabetes report states that no food or water restrictions are needed — the drug's pharmacokinetics are not affected by the prandial state. That is different from oral semaglutide, so the exact instructions depend on the specific drug: always follow the product label.